However, downregulation or loss of BCMA expression has been observed in a few MM patients after BCMA-directed CAR-T cell therapy, which mediates multiple myeloma resistance to anti-BCMA CAR-T therapies [15–17, 53]. Here, TNFRSF17 is linked to plasma cell myeloma.